Moreover, levels of pTau were significantly elevated in early converters in comparison to late converters, while a baseline Aβ42/p-tau ratio predicted the AD development within 9.2 years with a sensitivity of 88%, specificity of 90%, negative predictive value of 86% and positive predictive value of 91%. Here, MAPT is linked to Alzheimer disease.